Use of cilostazol in percutaneous coronary interventions;El uso de Cilostazol en la Intervención Coronaria Percutánea

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 839-850

  Rogers Dr , Kelly C ^a,b   Faircloth, Jenna M ^c   Finks, Shannon W ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet agents; Cilostazol; Percutaneous coronary intervention; Triple therapy

Indexed keywords

ACETYLSALICYLIC ACID; AMRINONE; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DILTIAZEM; ENOXIMONE; ERYTHROMYCIN; FLUOXETINE; MILRINONE; OMEPRAZOLE; PLACEBO; PRASUGREL; PROTEIN P21; PROTEIN P53; PYRROLE DERIVATIVE; SIMVASTATIN; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE;

ANGIOCARDIOGRAPHY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BARE METAL STENT; BLEEDING; BLOOD CLOTTING DISORDER; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DEATH; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RATE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MEDLINE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEOINTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESTENOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SILENT MYOCARDIAL ISCHEMIA; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TICLOPIDINE; VASODILATOR AGENTS;

EID: 84862251505     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q765     Document Type: Article

References (51)

1. Gurbel PA, Tantry US. Clopidogrel resistance? Thrombos Res 2007;120: 311-21. DOI 10.1016/j.thromres.2006.08.012
2. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-9. DOI 10.1111/j.1538-7836.2005.01751.x
3. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5. DOI 10.1161/01.CIR.0000130846.46168.03
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001-15. DOI 10.1056/NEJMoa0706482
5. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923-32. DOI 10.1161/CIRCULATIONAHA.107.740324
6. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction) Analysis. J Am Coll Cardiol 2008;51:2028-33. DOI 10.1016/j.jacc.2008.04.002
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. DOI 10.1056/NEJMoa0904327
8. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: a meta-analysis of randomized trials. JAMA 2005;294:819-25. DOI 10.1001/jama.294.7.819
9. Dangas GD, Bimmer EC, Caixeta A, et al. In-stent restenosis in the drugeluting stent era. J Am Coll Cardiol 2010;56:1897-907. DOI 10.1016/j.jacc.2010.07.028
10. Package Insert. Pletal (cilostazol). Rockville, MD: Otsuka America Pharmaceutical, Inc., May 2007.
11. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscles cells. Biochem Pharmacol 1994;48:827-35. DOI 10.1016/0006-2952(94)90062-0
12. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84:511-4. DOI 10.1016/S0002-9149(99)00368-9
13. Hashiguchi M, Ohno K, Nakazawa R, Kishino S, Mochizuki M, Shiga T. Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc DrugsTher 2004;18:211-7. DOI 10.1023/B:CARD.0000033642.49162.04
14. Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 2005;95:859-62. DOI 10.1016/j.amjcard.2004.12.012
15. Kubota Y, Kichikawa K, Uchida H, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol 1995;30:532-7.
16. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-8. DOI 10.1016/j.amjcard.2007.05.032
17. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6. DOI 10.1161/01.CIR.100.1.21
18. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112: 2826-32. DOI 10.1161/CIRCULATIONAHA.104.530097
19. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000;86:499-503. DOI 10.1016/S0002-9149(00)01001-8
20. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002;2:S14-9. DOI 10.1046/j.1463-1326.2002.0040s2s14.x
21. Kunishima T, Musha H, Eto F. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997;19:1058-66. DOI 10.1016/S0149-2918(97)80058-6
22. El-Beyrouty C, Spinler S. Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. Ann Pharmacother 2001;35:1108-13. DOI 10.1345/aph.10253
23. Lee SW, Park SW, Kim YH et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). Am Coll Cardiol 2008;51:1181-7. DOI 10.1016/j.jacc.2007.11.049
24. Lee S-W, Kook-Jin C, Seong-Wook P, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from DECLARE-DIABETES AND-LONG trials). Am J Cardiol 2010;105:168-73. DOI 10.1016/j.amjcard.2009.08.667
25. Lee SW, Park SW, Hong MK et al. Triple versus dual antiplatelet therapy after coronary stenting; impact on stent thrombosis. J Am Coll Cardiol 2005;46:1833-7. DOI 10.1016/j.jacc.2005.07.048
26. Chen Y, Lu Y, Jin Z, Yean F, Lu S. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J 2006;119:360-6.
27. Min P, Jung J, Ko Y, Choi D, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting. A quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007;71:1685-90. DOI 10.1253/circj.71.1685
28. Han Y, Li Y, Wang S, Jing Q, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9. DOI 10.1016/j.ahj.2009.01.006
29. Suh J, Lee S, Park K, Lee H, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial. J Am Coll Cardiol 2011;57:280-9. DOI 10.1016/j.jacc.2010.08.631
30. Zhang Z, Foster JK, Kolm P, et al. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 2006;152:770-6. DOI 10.1016/j.ahj.2006.03.018
31. Angiolillo D, Shoemaker S, Bhaloo D, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 2007;115:708-16. DOI 10.1161/CIRCULATIONAHA.106.667741
32. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008;29:2202-11. DOI 10.1093/eurheartj/ehn367
33. Chen KY, Rha SW, Li YJ et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119: 3207-14. DOI 10.1161/CIRCULATIONAHA.108.822791
34. Lee S-W, Park S-W, Yun S-C, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010;159:284-91. DOI 10.1016/j.ahj.2009.11.014
35. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9. DOI 10.1001/archinte.167.15.1593
36. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154: 221-31. DOI 10.1016/j.ahj.2007.04.014
37. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33. DOI 10.1016/j.jacc.2005.08.058
38. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66. DOI 10.1016/j.jacc.2006.10.050
39. Jeong YH, Kim IS, Park YP, et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150mg/day. JACC Cardiovasc Interv 2010;3:731-41. DOI 10.1016/j.jcin.2010.05.007
40. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndrome. J Am Coll Cardiol 2011;58:467-73. DOI 10.1016/j.jacc.2011.04.017
41. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001Guidelines for Percutaneous Coronary Intervention). http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf. DOI 10.1161/CIRCULATIONAHA.105.170815 (accessed 2012 Feb 9).
42. Jeong Y-H, Lee S-W, Choi B-R, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE. J Am Coll Cardiol 2009;53:1101-9. DOI 10.1016/j.jacc.2008.12.025
43. Jeong YH, Hwang JY, Kim IS et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010;3: 17-26. DOI 10.1161/CIRCINTERVENTIONS.109.880179
44. Duk-Woo Park. Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI). http://www.clinicaltrials.gov/ct2/show/NCT01346865 (accessed 2011 Dec 2).
45. Gyeongsang National University Hospital. Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism (ACCELAMI 2C19). http://www.clinicaltrials.gov/ct2/show/NCT00915733 (accessed 2011 Dec 2).
46. Gyeongsang National University Hospital. ACCEL-LOADING-ACS study. http://www.clinicaltrials.gov/ct2/show/NCT01354808 (accessed 2011 Dec 2).
47. Shenyang Northern Hospital. Triple versus dual antiplatelet therapy in patients undergoing coronary stent implantation. http://www.clinicaltrials.gov/ct2/show/NCT00404716 (accessed 2011 Dec 2).
48. CardioVascular Research Foundation, Korea. Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent (DECLARELONG). http://www.clinicaltrials.gov/ct2/show/NCT00589927 (accessed 2011 Dec 2).
49. Dio. Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After BioMatrix Stent Implantation (ABCD). http://www.clinicaltrials.gov/ct2/show/NCT01192724 (accessed 2011 Dec 2).
50. Korea University Guro Hospital. Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients (SILOAM). http://www.clinicaltrials.gov/ct2/show/NCT01261832 (accessed 2011 Dec 2).
51. Shenyang Northern Hospital. Effects of intensive antiplatelet therapy for patients with clopidogrel resistance after coronary stent implantation. http://www.clinicaltrials.gov/ct2/show/NCT01094457 (accessed 2011 Dec 2).